{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination induces type I interferon-linked changes that expand antigen presentation in tumors.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        },
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Combining intratumoral mRNA vaccination with checkpoint blockade improved tumor control in mouse experiments.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
          "line_ref": "L36"
        },
        {
          "quote": "ICI-only treatment had limited activity in low-immunogenic baseline settings.",
          "line_ref": "L37"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C03",
      "claim": "In the retrospective metastatic cohort, prior SARS-CoV-2 mRNA vaccination was associated with improved survival during ICI treatment.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
    },
    {
      "claim_id": "C04",
      "claim": "The sensitization effect depends on mRNA-triggered type I interferon signaling rather than lipid particles alone.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "Findings from these perturbation controls were produced in preclinical systems and may not translate identically across all human tumors."
    }
  ]
}
